Skip to content

Welcome to Discover Pharma! Today is : November 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

rare diseases

  • Clinical & Regulatory

    Late-breaking elafibranor data shows potential in primary sclerosing cholangitis (PSC)

    May 5, 2026
Previous45

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ryvu reports preclinical results for novel ADC payload
    Categories: Drug Discovery & Development, Research & Development
  • Kindeva wins $226 million contract for nerve agent antidote autoinjectors
    Categories: Manufacturing & Supply Chain
  • Nabsys launches RepX for repeat expansion analysis
    Categories: Genomics and sequencing
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top